Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.94 [0.84, 1.06]
1317 participants
High
Progression‐free survival · people with cutaneous melanoma
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.9 [0.83, 0.99]
964 participants
High
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.36 [1.12, 1.66]
770 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.35 [1.14, 1.61]
631 participants
High
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 1.07 [0.91, 1.25]
398 participants
High
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.27 [1.02, 1.58]
1885 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.6 [0.45, 0.81]
324 participants
Moderate
Progression‐free survival · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.69 [0.52, 0.92]
324 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.71 [0.96, 3.03]
324 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 0.68 [0.09, 5.32]
324 participants
Low
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.76 [0.63, 0.92]
502 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.28 [0.92, 1.77]
1157 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.69 [1.19, 2.42]
1142 participants
Moderate
Overall survival† · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.81 [0.65, 1.01]
1157 participants
Low
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Other therapies (cryotherapy) changes short‐term hair regrowth ≥ 75% compared with other therapies (fractional CO2 laser) (very low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found